Definitive Contract HDTRA111C0008

This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...

The Office of the Assistant Secretary for Preparedness and Response awarded a $61.98 million definitive cost-plus-fixed-fee contract to The Charles Stark Draper Laboratory, Inc. on September 29, 2023, for the development of a medical countermeasure evaluation platform. The platform will integrate vascular-immune and small intestine-immune organ-on-chip models with molecular assays, omics-based technologies, and advanced analytical methods for biomarker discovery. Work will be performed in...

Ceramedix Holding, LLC was awarded a $4.22M cost-plus-fixed-fee definitive contract by the National Institute of Allergy and Infectious Diseases on July 1, 2023, to develop anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The contract, with performance completing June 30, 2027, supports the NIH's broader mission to develop safe and effective countermeasures that reduce radiation-associated mortality and morbidity in mass casualty incidents....

This $38,243,034.02 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, which has no set-aside designation, is for the development of medical countermeasures through planned clinical trials and outbreak preparedness. This contract builds on...

This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to SRI International, a non-profit research and development institute. The contract, valued at $715,633.86, is for radiation/nuclear medical countermeasure (MCM) product development support services, specifically the formulation of 3,4,3-Li(1,2-HOPO). This contract is not a set-aside and is part of a...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $16.5 million Other Transaction Agreement to Rigel Pharmaceuticals Inc. to support the development of a therapeutic to treat COVID-19. The prototype effort will take place in South San Francisco, California through May 2023. No set-aside designation was applied to this award made under the "COVID-19" PROTOTYPE DEVELOPMENT OF A THEREAPUTIC TO TREAT COVID-19 solicitation. As the...

The U.S. Army's Research, Development and Engineering Command awarded a Small Business Technology Transfer (STTR) Phase II contract to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology firm specializing in antibody-based therapeutics and medical countermeasures against infectious diseases. The $1.5 million definitive contract, awarded July 28, 2020, with completion targeted for February 28, 2023, operates under a cost-plus-fixed-fee structure and includes a total small business...

This federal contract award to Innovation Pathways, LLC, a for-profit limited liability company, is for the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA Animal Rule. The $3,499,688.00 cost-plus-fixed-fee contract was awarded by the National Institute of Allergy and Infectious Diseases, a civilian agency, and has no set-aside designation. The contract work supports research and development...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.7 million definitive contract to Arisan Therapeutics Inc. on September 22, 2023, to conduct non-clinical Good Laboratory Practice (GLP) in vivo genotoxicity and reproductive toxicology studies, as well as GLP development and reproductive and developmental toxicology (DART) studies. The contract, which runs through December 31, 2026, carries a cost-plus-fixed-fee pricing structure and does not include a set-aside...

This is a $330,136,249.00 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to 4J Therapeutics Inc. to demonstrate the versatility and efficacy of their programmable antiviral technology platform. The purpose is to assemble a preclinical package for LNA14 and perform a Phase 1a study in healthy adults. The contract is not set aside and is the result of a Broad Agency Announcement (BAA) solicitation issued by the Biomedical Advanced...